Inventiva (IVA) — supplier map and commercial signals for capital-hungry clinical-stage biotech

Inventiva is a clinical-stage biopharmaceutical company that develops oral small-molecule therapies and funds operations primarily through equity markets and financing programs rather than product revenue. The company monetizes by financing clinical development via public offerings, at-the-market sales and market-microstructure contracts that support liquidity for its American Depositary Shares and ordinary shares listed in the U.S. and Europe. For investors evaluating supplier risk, the balance of underwriting banks, equity capital markets advisors, liquidity providers and investor-relations firms shapes both access to capital and market stability. Learn more about supplier risk profiles and market signals at https://nullexposure.com/.

Executive summary: capital markets relationships drive the operating model

Inventiva’s supplier footprint in the record set is dominated by capital markets counterparties and communications firms rather than traditional R&D or manufacturing vendors. That pattern signals a company operating model that is financing-first — transactional underwriter relationships, an active ATM, a formal liquidity contract and outsourced investor communications. These suppliers are critical to near-term funding and public market presence; the absence of long-term, operational suppliers in the record set reinforces that capital access, not supply chain delivery, is the immediate operational dependency.

Key takeaways:

• Primary monetization: equity issuance and ATM programs to support clinical spend and trials.
• Concentration risk: heavy reliance on a small set of underwriters and a single liquidity manager.
• Contracting posture and maturity: relationships are event-driven and short-to-medium term, anchored around discrete financing and liquidity agreements. Explore how these counterparty relationships affect valuation and execution risk: https://nullexposure.com/.

What the relationships tell investors about contracting posture, concentration and criticality

Absent explicit long-term supplier contracts in the captured results, the company-level signals are clear. Inventiva’s contracting posture is transactional and capital-market oriented: it appoints underwriters and sales agents on offerings, uses equity capital markets advisors for strategic placement, and maintains a liquidity contract with a specialized broker. That posture creates concentration: a handful of banks and one liquidity provider carry outsized operational impact on fundraising and market access. Criticality is high for those counterparties because successful capital raises and orderly trading materially affect cash runway and investor confidence. Maturity of these relationships is tactical — tied to financing cycles and liquidity reporting — rather than embedded vendor partnerships for R&D or manufacturing.

Below I map every supplier relationship found in the public reporting and press releases so you can assess counterparty risk and governance signals.

Detailed supplier relationships and source notes

Leerink Partners / Leerink Partners LLC

Leerink Partners served as an underwriter on Inventiva’s upsized public offering, taking syndicate responsibilities and distribution tasks for the equity raise. According to Inventiva’s press release announcing the pricing of the offering dated November 13, 2025, Leerink and Piper Sandler were underwriters for the transaction (https://www.globenewswire.com/news-release/2025/11/13/3187489/).

Piper Sandler / Piper Sandler & Co. (PIPR)

Piper Sandler acted as a co-underwriter on the offering and as a sales-agent for the company’s ATM program, indicating a multi-role engagement across both block issuance and ongoing at-the-market placement. See the company announcements relating to the November 2025 offering and the October 2025 ATM program (https://www.globenewswire.com/news-release/2025/11/13/3187489/; https://www.globenewswire.com/news-release/2025/10/14/3166628/).

Namsen Capital

Namsen Capital was appointed as Equity Capital Markets Advisor to Inventiva in connection with the same offering, a role that supports deal structuring and market placement strategy. This advisory engagement is disclosed in the November 13, 2025 press release (https://www.globenewswire.com/news-release/2025/11/13/3187489/).

Nasdaq (NDAQ)

Nasdaq is the listing venue for Inventiva’s American Depositary Shares (ADSs) and therefore a structural market supplier for trading infrastructure and compliance oversight. The company confirms its ADS listing on the Nasdaq Global Market in its November 2025 announcements (https://www.globenewswire.com/news-release/2025/11/17/3188828/).

Euronext

Euronext is the regulated market where Inventiva’s ordinary shares trade in Paris; dual-listing on Euronext supports European liquidity and shareholder access. The listing detail is included in the November 12 and November 17, 2025 releases (https://www.globenewswire.com/news-release/2025/11/12/3186831/; https://www.globenewswire.com/news-release/2025/11/17/3188828/).

ICR Healthcare

ICR Healthcare is the retained investor-relations and media contact for Inventiva, handling both media and investor communications tasks around the offering and leadership announcements. Multiple company press releases list ICR Healthcare for media and investor relations contact points in October–November 2025 (e.g., https://www.globenewswire.com/news-release/2025/11/12/3186831/; https://www.globenewswire.com/news-release/2025/10/01/3159217/).

Kepler Cheuvreux

Kepler Cheuvreux is the liquidity contract manager; Inventiva disclosed the liquidity account resources and the half-year review of that contract as of December 31, 2025, showing a formal market-making arrangement to support share liquidity in Europe. See the January 26, 2026 half-year review press release (https://www.globenewswire.com/news-release/2026/01/26/3225966/).

Westwicke, an ICR Company

Westwicke is referenced as an investor-relations contact for a clinical update in FY2024-era communications, implying engagement on biotech investor messaging and outreach. This appears in a Yahoo Finance distribution of the company’s clinical-results announcement (https://finance.yahoo.com/news/inventiva-announces-positive-results-phase-200000957.html).

Boehringer Ingelheim

Boehringer Ingelheim is cited in external clinical coverage as the manufacturer of a comparator diabetes product (empagliflozin/Jardiance) referenced in trial reporting that contextualizes Inventiva’s lanifibranor data; this is a scientific/clinical reference rather than a commercial supplier relationship to Inventiva. Coverage by Liver Disease News referenced the combination arm that included Boehringer Ingelheim’s product in FY2024 clinical discussions (https://liverdiseasenews.com/news/interim-analysis-fatty-liver-disease-patients-see-benefits-with-lanifibranor/).

Brunswick Group

Brunswick Group is listed as a media contact in press distributions tied to clinical results, indicating an external communications or PR role supporting Inventiva’s announcements in FY2024 communications (Finance release distributed via Yahoo/Brunswick listings) (https://finance.yahoo.com/news/inventiva-announces-positive-results-phase-200000957.html).

Risk implications and investor action points

• Funding dependency: The supplier map shows Inventiva’s near-term viability depends on successful execution with a concentrated set of underwriters and an active liquidity contract; these relationships are critical to maintaining cash runway and orderly trading.
• Concentration risk: The same firms (Leerink/Piper Sandler and Kepler Cheuvreux) recur in the financing and liquidity roles — a small counterparties set that creates single-point operational risk if any partner withdraws.
• Communications control: Outsourced IR and PR vendors (ICR/Westwicke/Brunswick) centralize public messaging; governance around disclosure timing and investor outreach is therefore mediated by these third parties.

Investors should monitor subsequent SEC filings and press kits for amendments to underwriting agreements, updates to the liquidity contract, or changes in sales-agent arrangements. For a deeper counterparty risk assessment and monitoring tools, visit https://nullexposure.com/.

Closing recommendation

For investors and operators, the profile is straightforward: Inventiva is capital markets driven and reliant on a narrow set of capital-market suppliers for financing and liquidity. Underwriters, an equity capital markets advisor, a liquidity manager and outsourced IR/PR firms together shape execution risk and the company’s market presence. Track financing notices, liquidity-account disclosures and any shifts in these supplier relationships as the primary operational signals for near-term valuation movements.

If you need a detailed counterparty-risk brief or a monitoring setup for these suppliers, start a review at https://nullexposure.com/.